Omnipod® 5: Tubeless, automatic insulin adjustments
Omnipod 5, the first and only tubeless, automated insulin delivery system to integrate with Dexcom G6, is now available. Omnipod 5 helps simplify life with diabetes: no multiple daily injections, tubes, or fingersticks* necessary!
- Cleared for people with type 1 diabetes aged 2 years and older
- Helps keep you in range day and night1,2
- Monitor your glucose levels and insulin dosing all with the option for full control right from your compatible smartphone†.
- Just like Omnipod DASH®️, it includes a waterproof‡ tubeless insulin Pod that can be worn almost anywhere you’d inject insulin.
- Each Pod still lets you trade multiple daily injections for up to 3 days (72 hours) of continuous insulin delivery.
Now, the Pod is automated, CGM integrated, and highly anticipated simplifying life in so many ways.
†For a list of compatible smartphone devices visit omnipod.com/compatibility.
‡The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Controller is not waterproof.
3 Simple Parts
To the Omnipod 5 Automated Insulin Delivery System
Omnipod 5 App*
Take full control of the Pod from the Omnipod 5 App on a compatible smartphone* or use the free Controller, included at no additional charge with your first prescription for the Omnipod 5 Intro Kit.
Tubeless, wearable and waterproof, the state-of-the-art Pod, with built in SmartAdjust™ technology, sits right on your body and automatically adjusts insulin delivery for up to 3 days or 72 hours.
Dexcom G6 CGM System
Continuously sends glucose readings to the Pod, so you can get real-time data without the fingersticks*. A separate prescription is required for the Dexcom G6 CGM. The Dexcom G6 is sold separately and must be used with the Dexcom G6 mobile app. The Dexcom G6 receiver is not compatible.
Always adjusting, so you don’t have to
With SmartAdjust™ technology, Omnipod 5 and the Dexcom G6 CGM* are in constant communication, enabling automatic insulin adjustments to help improve time in range.1,2
“The Omnipod 5 has definitely allowed me to focus more on life and less on Type 1 diabetes.”
Innovation, at your fingertips
Omnipod 5 boasts outstanding design and engineering, recognized by the CES Innovation Awards in 2022. Plus, you have the option to control it all from a compatible smartphone* through the
Omnipod 5 App.
If your phone isn’t compatible, you can use the free Omnipod 5 Controller, included at no additional charge with your Omnipod 5
*For a list of compatible smartphone devices visit omnipod.com/compatibility.
Check Your Coverage for Omnipod Products
Before you can get started on Omnipod, our team will take a close look at your insurance benefits. We’ll check your coverage* for both the Omnipod® 5 System and Omnipod DASH® so you can see all your options. Here’s how that works:
- Fill out the form below to get started
- Check your email and electronically sign the DocuSign form
- Once complete, an Omnipod Specialist will check your coverage and get back to you within three business days
*Available products subject to current insurance coverage and product indication for use. Insulet can only support onboarding for those customers within the product indication. The Omnipod® 5 System is currently indicated for use by individuals with type 1 diabetes, 6 years of age and older. Feel free to contact your doctor regarding all products that might be right for you.
1.Study in 80 people with T1D aged 2 -5.9 yrsinvolving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose overnight from CGM in standard therapy vs Omnipod 5 = 38.4% vs. 16.9%. Average time with high blood during daytime from CGM in standard therapy vs Omnipod 5 = 39.7% vs . 3 3.7%. Average time with low blood glucose overnight from CGM in standard therapy vs. Omnipod 5= 3.41% vs. 2.13%. Average time with low blood glucose during daytime from CGM in standard therapy vs. Omnipod 5 = 3.44% vs. 2.5 7%. SherrJL, et al. Diabetes Care (2022).
2. Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average day time (6AM-12AM) in Target Glucose range (from CGM) in adults/adolescents and children for standard therapy vs Omnipod 5 = 64.8% vs. 72.5%; 51.5% vs. 64.6%. Average overnight (12AM-6AM) in Target Glucose range (from CGM) in adults/adolescents and children for standard therapy vs Omnipod 5 = 64.3% vs. 78.1%; 55.3% vs. 78.1%. Brown et al. Diabetes Care (2021)
The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires a prescription. The Omnipod 5 System is compatible with the following U-100 insulins: NovoLog®, Humalog®, and Admelog®.
The Omnipod 5 ACE Pump (Pod) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The Omnipod 5 ACE Pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. SmartAdjust™ technology is intended for use with compatible integrated continuous glucose monitors (iCGM) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and pause delivery of insulin based on current and predicted glucose values. The Omnipod 5 SmartBolus Calculator is intended to calculate a suggested bolus dose based on user-entered carbohydrates, most recent sensor glucose value (or blood glucose reading if using fingerstick), rate of change of the sensor glucose (if applicable), insulin on board (IOB), and programmable correction factor, insulin to carbohydrate ratio, and target glucose value.
WARNING: SmartAdjust technology should NOT be used by anyone under the age of 2 years old. SmartAdjust technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population.
The Omnipod 5 System is NOT recommended for people who are unable to monitor glucose as recommended by their healthcare provider, are unable to maintain contact with their healthcare provider, are unable to use the Omnipod 5 System according to instructions, are taking hydroxyurea as it could lead to falsely elevated CGM values and result in over-delivery of insulin that can lead to severe hypoglycemia, and do NOT have adequate hearing and/or vision to allow recognition of all functions of the Omnipod 5 System, including alerts, alarms, and reminders. Device components including the Pod, CGM transmitter, and CGM sensor must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components. Visit www.omnipod.com/safety for additional important safety information.
WARNING: DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.